What are the available payment terms?

Terms of Payment include LC (Letter of Credit) and T/T (Telegraphic Transfer).

What is the average lead time for orders?

The peak season lead time is one month.

Which markets do the products serve?

Products are sold to South America, Southeast Asia, Africa, Oceania, and the Middle East.

Ringer Lactate Injection/Sodium Ringer Lactate for Injection

Name: Ringer Lactate Injection/Sodium Ringer Lactate for Injection
Brand: Shijiazhuang No. 4 Pharmaceutical Co., Ltd.
SKU: 2091635712

Hebei, ChinaShijiazhuang No. 4 Pharmaceutical Co., Ltd.

US$0.17-0.20

20,000 Pieces

Sample price:US$0.20/piece.Request sample

Product profile

Customization

Available

Application

Internal Medicine

Usage Mode

Injection

Suitable for

Elderly, Adult

State

Liquid

Shape

Injection

Type

Inorganic Chemicals

Pharmaceutical Technology

Chemical Synthesis

Transport Package

500ml Plastic Bottle, 30bottles/Carton

Specification

500ml/bottle, 30bottles/carton

Origin

China

HS Code

30049090

Production Capacity

1000000pieces/Year

Key features

Corrects Acidosis: Sodium lactate metabolizes to sodium bicarbonate to correct metabolic acid toxicosis.

Electrolyte Balance: Adjusts equilibrium of humor electrolyte acid and alkali for dehydration treatment.

Large Scale Production: Yearly output exceeds 1200 million bottles with advanced soft plastic bottle packing.

GMP Certified: Manufactured with GMP approval by SFDA of China ensuring high quality standards.

Global Market Reach: Products sold to South America, Africa, Asia, Oceania, and Middle East regions.

Established Manufacturer: Shijiazhuang No.4 Pharmaceutical Co., Ltd. established in 1948 with 3000+ employees.

Clear Liquid Form: Product is a colorless clear liquid containing sodium lactate, sodium chloride, etc.

Multiple Dosage Options: Available in 500 ml, 250 ml, and 100 ml soft plastic bottle specifications.

Company profile

Shijiazhuang No. 4 Pharmaceutical Co., Ltd.

Hebei, China

Business Type: Manufacturer/FactoryExport Year: 2002-01-01Nearest Port: Tianjin Xingang, Qingdao, ShanghaiAverage Response Time: ≤24hTerms of Payment: LC, T/TInternational Commercial Terms(Incoterms): FOB, CFR, CIF, CIP, EXW

AI-Powered supplier vetting

SummaryShijiazhuang No. 4 Pharmaceutical Co., Ltd. is identified as a Chinese public pharmaceutical manufacturer based in Hebei, with products spanning infusion solutions, injections, tablets, capsules, inhalation products, and other medical materials. The supplier reports ISO 9001, ISO 14001, and GMP certifications, more than ten production lines, automated and information-based production and logistics processes, and substantial stated output across several dosage forms. Its export activity began in 2002, although exports represent only 1%–10% of total sales. The company describes integrated R&D, manufacturing, and marketing capabilities, but the provided information does not establish specific after-sales programs, customization services, or named customer cases. Financial strength cannot be assessed because financial data is excluded.

Supplier typeThe supplier is explicitly classified as a Manufacturer/Factory and is described as an integrated pharmaceutical enterprise covering R&D, industrial production, and marketing. Its listed business covers health and medicine products, including injections, infusion solutions, tablets, capsules, and related dosage forms.

CertificationsThe supplier reports ISO 9001, ISO 14001, and GMP certifications. It also states that production is organized strictly according to GMP requirements, providing explicit evidence of formal quality, environmental, and pharmaceutical manufacturing systems.

R&D capabilityThe supplier describes an integrated R&D, production, and marketing model, reports 50 R&D engineers, and states that its production lines integrate leading equipment and technology at an international advanced level. This supports established technical and development capability, although no specific patents, new-product results, or R&D investment details are provided.

Production capacityProduction capability is strongly supported by more than ten production lines, automated and information-based production and logistics processes, and stated annual outputs of 1.5 billion large-volume injection units and 1 billion units each for tablets, capsules, and small-volume injections. The company also reports more than ten international advanced infusion-solution lines and exports through both agency and self-operated channels.